Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Rigosertib inhibits tumor cell growth and survival by activating cJun N-terminal kinases 1/2 (JNK1/2) through reactive oxygen species (ROS).
• JNK1/2 signaling is a critical regulator of cellular processes, including ROS production and cell death.
• The protein p66Shc plays a role in oxidative stress and cell death, and its function is modulated by JNK1/2 phosphorylation.

Purpose of the Study:

• To investigate the role of p66Shc as a downstream effector in the Rigosertib-induced cell death pathway.
• To elucidate the mechanistic link between Rigosertib, ROS, JNK1/2, and p66Shc in cancer cells.

Main Methods:

• Utilized cell-based assays to examine Rigosertib's effects on ROS production, DNA damage, and cell death.
• Investigated the phosphorylation status and activity of JNK1/2 and p66Shc in response to Rigosertib treatment.
• Employed molecular biology techniques to determine the functional relationship between p66Shc and JNK1/2 in Rigosertib-mediated signaling.

Main Results:

• Rigosertib treatment led to increased ROS production, DNA damage, and cell death in tumor cells.
• Rigosertib-induced ROS activated JNK1/2, which subsequently phosphorylated p66Shc.
• Phosphorylated p66Shc was identified as a crucial effector mediating Rigosertib's pro-oxidant and cell death effects.

Conclusions:

• p66Shc acts as a critical JNK1/2 effector downstream of Rigosertib-induced ROS production, DNA damage, and cell death.
• This pathway involving p66Shc may represent a common mechanism by which Rigosertib suppresses tumor cell growth.
• Targeting the Rigosertib-p66Shc axis could offer a novel therapeutic strategy for cancer treatment.